array:23 [ "pii" => "S2529912319300749" "issn" => "25299123" "doi" => "10.1016/j.artere.2019.11.004" "estado" => "S300" "fechaPublicacion" => "2019-11-01" "aid" => "511" "copyrightAnyo" => "2019" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2019;31:261-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S0214916819301391" "issn" => "02149168" "doi" => "10.1016/j.arteri.2019.10.005" "estado" => "S300" "fechaPublicacion" => "2019-11-01" "aid" => "511" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Invest Arterioscl. 2019;31:261-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 23 "formatos" => array:2 [ "HTML" => 19 "PDF" => 4 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "La asignación de factor impacto a Clínica e Investigación en Arteriosclerosis. Un objetivo cada vez más cercano" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "261" "paginaFinal" => "262" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Assigning an impact factor to the journal <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span>. An increasingly achievable objective" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Lahoz, Josep Ribalta, Xavier Pintó" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Carlos" "apellidos" => "Lahoz" ] 1 => array:2 [ "nombre" => "Josep" "apellidos" => "Ribalta" ] 2 => array:2 [ "nombre" => "Xavier" "apellidos" => "Pintó" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912319300749" "doi" => "10.1016/j.artere.2019.11.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912319300749?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916819301391?idApp=UINPBA00004N" "url" => "/02149168/0000003100000006/v3_202004080610/S0214916819301391/v3_202004080610/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2529912319300828" "issn" => "25299123" "doi" => "10.1016/j.artere.2019.11.006" "estado" => "S300" "fechaPublicacion" => "2019-11-01" "aid" => "488" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2019;31:263-70" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Security profile of direct anticoagulants. Preferred use in atrial fibrillation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "263" "paginaFinal" => "270" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Perfil de seguridad de los anticoagulantes directos. Uso preferente en fibrilación auricular" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Inmaculada Roldán Rabadán, María Alonso de Leciñana, Raquel Barba Martín, José Antonio Páramo Fernández" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "Roldán Rabadán" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Alonso de Leciñana" ] 2 => array:2 [ "nombre" => "Raquel" "apellidos" => "Barba Martín" ] 3 => array:2 [ "nombre" => "José Antonio" "apellidos" => "Páramo Fernández" ] 4 => array:1 [ "colaborador" => "the Cardiovascular Thrombosis Forum" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916819300440" "doi" => "10.1016/j.arteri.2019.03.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916819300440?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912319300828?idApp=UINPBA00004N" "url" => "/25299123/0000003100000006/v1_201912172230/S2529912319300828/v1_201912172230/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S2529912319300816" "issn" => "25299123" "doi" => "10.1016/j.artere.2019.11.005" "estado" => "S300" "fechaPublicacion" => "2019-11-01" "aid" => "491" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Clin Investig Arterioscler. 2019;31:251-60" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "251" "paginaFinal" => "260" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La vitamina B<span class="elsevierStyleInf">3</span> altera el transporte reverso del colesterol en ratones con deficiencia en apolipoproteína E" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2265 "Ancho" => 2499 "Tamanyo" => 240219 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Effect of NAM on metabolic fate of non-HDL in plasma in KOE mice. In vivo kinetics of [<span class="elsevierStyleSup">3</span>H]-cholesterol oleoyl ether non-HDL in plasma (panel A) and liver (panel B). Autologous <span class="elsevierStyleSup">3</span>H]-cholesterol oleoyl ether non-HDL were injected intravenously into fasted mice. The amounts of radioactivity remaining in the plasma (expressed as the average percentage<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SEM, <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5–6 mice) were indicated at the indicated times after injection over a period of 24<span class="elsevierStyleHsp" style=""></span>h. Inset: FCR and synthetic rates of the different mouse groups. Oral fat gavage (OFG) assays in NAM-treated and untreated mice. An olive oil-based emulsion containing radiolabeled [<span class="elsevierStyleSup">3</span>H]-cholesterol was prepared and oral gavaged into KOE mice. Radiolabeled [<span class="elsevierStyleSup">3</span>H]-cholesterol was, respectively, measured in plasma (panel C) and in the liver (panel D) after a single bolus of 200<span class="elsevierStyleHsp" style=""></span>μL of radiolabeled olive oil-based emulsion (20<span class="elsevierStyleHsp" style=""></span>μCi per mouse) at the times indicated over a period of 24<span class="elsevierStyleHsp" style=""></span>h. Results are expressed as the average percentage vs. injected dose<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SEM of individual animals (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>5 mice at each time point). In panels A and B, differences between mean values were assessed by the nonparametric <span class="elsevierStyleItalic">U</span> Mann–Whitney test. Specifically, *<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05 compared with the untreated group. Inset: area under the curve of [<span class="elsevierStyleSup">3</span>H]-cholesterol non-HDL after the OFG of the different mouse groups. Each data represents the mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SEM of 5 mice. In panels C and D, differences between mean values were assessed by the nonparametric Kruskal–Wallis test followed by Dunn's post-test; differences were considered significant when <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05. Specifically, *<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05 vs. untreated group. Abbreviations used: Un, untreated mice; Lo, low-dose, NAM-treated mice; Hi, high-dose, NAM-treated mice.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Karen Alejandra Méndez-Lara, David Santos, Núria Farré, Madalina Nicoleta Nan, Víctor Pallarès, Antonio Pérez-Pérez, Núria Alonso, Joan Carles Escolà-Gil, Francisco Blanco-Vaca, Josep Julve" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Karen Alejandra" "apellidos" => "Méndez-Lara" ] 1 => array:2 [ "nombre" => "David" "apellidos" => "Santos" ] 2 => array:2 [ "nombre" => "Núria" "apellidos" => "Farré" ] 3 => array:2 [ "nombre" => "Madalina Nicoleta" "apellidos" => "Nan" ] 4 => array:2 [ "nombre" => "Víctor" "apellidos" => "Pallarès" ] 5 => array:2 [ "nombre" => "Antonio" "apellidos" => "Pérez-Pérez" ] 6 => array:2 [ "nombre" => "Núria" "apellidos" => "Alonso" ] 7 => array:2 [ "nombre" => "Joan Carles" "apellidos" => "Escolà-Gil" ] 8 => array:2 [ "nombre" => "Francisco" "apellidos" => "Blanco-Vaca" ] 9 => array:2 [ "nombre" => "Josep" "apellidos" => "Julve" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912319300816?idApp=UINPBA00004N" "url" => "/25299123/0000003100000006/v1_201912172230/S2529912319300816/v1_201912172230/en/main.assets" ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Assigning an impact factor to the journal Clínica e Investigación en Arteriosclerosis. An increasingly achievable objective" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "261" "paginaFinal" => "262" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">There have been some very favourable events for the journal <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> [Clinical Practice and Research in Arteriosclerosis] in recent years. The fact that the journal was included in 2013 in the Medline database, created and managed by the United States National Library of Medicine, has given it worldwide visibility. This had a very positive impact on the journal's expansion, with a 60% increase in the number of original articles received, greater participation of the Latin American community and us starting to receive articles written in English. In early 2017, <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> was published simultaneously in Spanish and English, a momentous event in terms of increasing its international prominence. Also in recent years, we have significantly increased our publication of consensus documents and clinical guidelines, which have been an important source of citations. The above changes, just some of many, have resulted in a progressive increase in the number of manuscripts received while, at the same time, we have seen a steady increase in the citation indexes. For example, the CiteScore (<a href="https://www.scopus.com/sourceid/7200153133">https://www.scopus.com/sourceid/7200153133</a>), an index that measures the average number of citations received in a particular year, divided by all articles published in the journal in the three previous years, increased from 0.18 in 2014 to 0.84 in 2018. In November 2018, <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> was included in the WoS/Clarivate Emerging Sources Citation Index (ESCI), another important step for obtaining impact factor.</p><p id="par0010" class="elsevierStylePara elsevierViewall">If we were assigned impact factor, it would mean a substantial rise in the prestige of our society's journal and its consolidation as a high-level scientific journal in the international arena, and the present period is therefore key. Assigning of impact factor will also be fundamental for increasing the number and quality of papers submitted for publication in the journal.</p><p id="par0015" class="elsevierStylePara elsevierViewall">To obtain that impact factor for <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span>, the works selected for publication must have a high level of scientific quality. To achieve this, we have to be able to count on the collaboration and efforts of all members of the <span class="elsevierStyleItalic">Sociedad Española de Arteriosclerosis (SEA)</span> [Spanish Society of Arteriosclerosis] in sending high-quality scientific manuscripts. It is also necessary to have an Editorial Committee made up of a large and efficient team of reviewers. The reviewers, both in the clinical field and in experimental and clinical-epidemiological research, must assure that the review process is agile, rigorous, and capable of selecting and prioritising the articles that have the highest quality and interest, particularly for the scientific community associated with dyslipidaemia, atherogenic factors and vascular disease. With this goal, we have just appealed to all the members of the Society by email, inviting them to participate in the Editorial Committee as manuscript reviewers for the journal. We hope our appeal generates a large positive response.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Another important step in the evolution of <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> is the renewal of the Editorial Board. The Board needs to be made up of highly regarded experts, which should contribute to increasing the quality of the articles received and published in the journal and, at the same time, greater international projection.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In line with prestigious journals, as part of our journal's editorial team, we have created the figure of Associate Editor. This person will be an expert with the responsibility of working in a strategic area for the journal, and within that role, collaborating with the editors in all the steps designed to increase the number and quality of articles received and published in <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span>.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Last of all, we plan to include new members of the Latin American community in the Editorial Committee, in order to encourage their collaboration in the journal and increase the presence of studies carried out in Latin America, an area with which we feel closely linked. We hope our colleagues based there will do us the honour of contributing to further enhance the visibility of Latin American science in the journal and add the value for the journal of being a channel of expression for the scientists in that area. The future of <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> requires the collaboration of all members of the SEA and of the Society itself. As we said before, this is a very important time for the future of our journal. However, we have only arrived in this fortunate position thanks to the efforts of the successive editors and Editorial Committees, the authors, the professionals of the Elsevier publishing house and, without any doubt, the readers who, all together, have made this situation possible. The <span class="elsevierStyleItalic">Clínica e Investigación en Arteriosclerosis</span> editorial team would like to thank all of you for your excellent work and your trust, and ask that we continue moving forward together towards the great challenge of being assigned impact factor, a goal which is becoming increasingly within reach. When we achieve it, we will have taken a giant step towards consolidating the prestige of the journal in the international scientific community.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Carlos Lahoz Josep Ribalta Xavier Pintó</p><p id="par0040" class="elsevierStylePara elsevierViewall">Clinical Research Editor Basic Research Editor Editor in Chief</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/25299123/0000003100000006/v1_201912172230/S2529912319300749/v1_201912172230/en/main.assets" "Apartado" => array:4 [ "identificador" => "63723" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003100000006/v1_201912172230/S2529912319300749/v1_201912172230/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912319300749?idApp=UINPBA00004N" ]
Journal Information
Share
Download PDF
More article options
Editorial
Assigning an impact factor to the journal Clínica e Investigación en Arteriosclerosis. An increasingly achievable objective